Physician profile
Mitchell G Silverman
NPI 1184272452
$2,138.37
in general payments reported to CMS, 2019-2025
27 companies · $681 in 2025
The $681 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $33.80 · 2022: $663 · 2023: $316 · 2024: $445 · 2025: $681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,441.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $251.47 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $245.53 | 2022-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.43 | 2022-2024 | Jardiance |
| Edwards Lifesciences Corporation | $169.54 | 2022 | |
| Merck Sharp & Dohme LLC | $157.40 | 2022-2025 | Verquvo |
| Scpharmaceuticals INC. | $126.02 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $112.62 | 2024-2025 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $95.55 | 2022-2025 | Lifevest |
| Kestra Medical Technology Services, INC. | $79.88 | 2023-2025 | Assure Wcd |
| Pfizer INC. | $75.63 | 2022-2025 | |
| Atricure, INC. | $72.33 | 2023 | |
| Esperion Therapeutics, INC. | $63.26 | 2024-2025 | Nexletol |
| Cvrx, INC. | $58.44 | 2024-2025 | Barostim Neo System |
| Amgen INC. | $55.20 | 2022-2025 | Repatha |
| Abiomed | $48.04 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $47.76 | 2022-2023 | Rybelsus, Ozempic |
| Lexicon Pharmaceuticals, INC. | $47.44 | 2023-2024 | Inpefa |
| Boston Scientific Corporation | $37.13 | 2024-2025 | Watchman Access System |
| Daiichi Sankyo INC. | $25.00 | 2024 | Injectafer |
| Bridgebio Pharma, INC. | $24.12 | 2025 | Attruby |
| Sanofi-Aventis U.S. LLC | $20.96 | 2022 | |
| Heartflow, INC. | $20.18 | 2024 | |
| Convatec INC. | $20.07 | 2024 | |
| Medtronic, INC. | $19.94 | 2024 | Abre |
| Cashflow Solutions, LLC | $18.20 | 2025 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
| Chiesi USA, INC. | $16.27 | 2023 | Kengreal |
| Amarin Pharma, INC. | $15.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Silverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.